Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Acceleron Pharma logo — Accelerating drug discovery to transform patients' lives

Acceleron Pharma

Accelerating drug discovery to transform patients' lives

Founded 2003 United States Cambridge, United States 67 employees Post-IPO Equity Biotechnology, Health Care +2

General Information

Company Name Acceleron Pharma
Founded Year 2003
Location United States Cambridge, United States
Employees 67
Industries Biotechnology, Health Care, Manufacturing +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Acceleron Pharma. To contact Acceleron Pharma, visit acceleronpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Acceleron Pharma compare?

A PDF of Acceleron Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Acceleron Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Acceleron Pharma

Acceleron Pharma is a biotechnology company founded in 2003 with a clear vision encapsulated in their slogan, "Accelerating drug discovery to transform patients' lives." On November 22, 2021, the company underwent a significant change as it became a wholly-owned subsidiary of Merck & Co., Inc. This strategic move marks a pivotal moment in the company's growth trajectory, cementing its position to leverage the vast resources and global reach of Merck & Co. The company operates in the biotechnology, health care, manufacturing, and pharmaceutical industries, reflecting the diverse nature of its activities. Acceleron Pharma's last recorded investment was a Post-IPO Equity investment on June 30, 2020, underlining a continued interest in the company from potential investors. This development provides a glimpse into the evolving landscape of the pharmaceutical industry, signaling promising prospects for Acceleron Pharma's future endeavors as part of Merck & Co., Inc.

Business keywords: Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, Musculoskeletal Diseases, Cancer Therapeutics, Metabolic Disorders, Muscle Loss Therapies, Neuromuscular Diseases, Angiogenesis Therapies, Drug Discovery, Biotherapeutics, Cellular Proliferation, Differentiation Factors, Tissue Regeneration, Clinical Research

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Undisclosed -
30 Jun 2020
Post IPO Equity Undisclosed -
01 Jan 2019
Post IPO Equity Undisclosed -
20 Sep 2017
Post IPO Equity Undisclosed -
05 Jan 2016
Post IPO Equity Undisclosed -
22 Jan 2014
Post IPO Equity Undisclosed -
24 Sep 2013
Series D Undisclosed -
23 Dec 2011
Grant Undisclosed -
06 Jan 2011
Venture Series Unknown Undisclosed -
10 Jun 2010
Venture Series Unknown Undisclosed -
15 Dec 2009

View All 15 Funding Rounds

Acceleron Pharma Alternatives & Competitors

View All Alternatives
Acceleron Pharma vs
Angitia Biopharmaceuticals
Angitia Biopharmaceuticals United States

Developing innovative medicines to address serious musculoskeletal diseases

Series B
52 employees
Biopharma, Biotechnology
Acceleron Pharma vs
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals

Pioneering breakthroughs in genetic disorders and liver diseases using RNA interference technology.

Post-IPO Equity
201-500 employees
Biotechnology, Health Care
Acceleron Pharma vs
HemoShear Therapeutics
HemoShear Therapeutics United States

Developing new treatments for rare metabolic disorders

Debt Financing
27 employees
Biotechnology, Health Care
View all alternatives

FAQ About Acceleron Pharma

Accelerating drug discovery to transform patients' lives
Acceleron Pharma was founded in 2003.
Acceleron Pharma is headquartered in Cambridge, United States.
Acceleron Pharma operates in Biotechnology, Health Care, Manufacturing and Pharmaceutical. Its work centres on Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases and Musculoskeletal Diseases.
Acceleron Pharma has approximately 67 employees.
Acceleron Pharma has completed 15 funding rounds. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Acceleron Pharma include Angitia Biopharmaceuticals, Dicerna Pharmaceuticals, HemoShear Therapeutics, Navitor Pharmaceuticals, Edgewise Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Acceleron Pharma and Angitia Biopharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Acceleron Pharma, https://bouncewatch.com/company/acceleron-pharma, updated 8 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes